Download PDF
Dtsch Med Wochenschr 2009; 134(20): 1062-1066
DOI: 10.1055/s-0029-1222570
Aktuelle Diagnostik & Therapie | Review article
Diabetologie
© Georg Thieme Verlag KG Stuttgart · New York

Stellenwert Inkretin-basierter Therapieformen

The value of incretin based therapiesB. Gallwitz1
  • 1Medizinische Klinik IV, Universitätsklinikum Tübingen
Further Information

Publication History

eingereicht: 17.1.2008

akzeptiert: 26.2.2009

Publication Date:
06 May 2009 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Typ-2-Diabetes - antidiabetische Therapie - Inkretine - GLP-1 - Inkretin-Mimetika - DPP-4-Inhibitoren

Keywords

type 2 diabetes - antidiabetic therapy - incretins - GLP-1 - incretin mimetics - DPP-4 inhibitors

Literatur

  • 1 Ahrén B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.  Vasc Health Risk Manag. 2008;  4 383-394
    Google Scholar
  • 2 Ahrén B, Foley J E. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.  Int J Clin Pract. 2008;  62 Suppl 8-14
    Google Scholar
  • 3 Baggio L L, Drucker D J. Therapeutic approaches to preserve islet mass in type 2 diabetes.  Annu Rev Med. 2006;  57 265-281
    Google Scholar
  • 4 Bunck M C, Diamant M, Corner A. et al . Beta-cell function and glycemic control following one year exenatide therapy, and after 12 week wash out, in patients with type 2 diabetes.  Diabetes. 2008;  57, Suppl. 1 A32
    Google Scholar
  • 5 Courrèges J P, Vilsbøll T, Zdravkovic M. et al . Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.  Diabet Med. 2008;  25 1129-1131
    Google Scholar
  • 6 Drucker D J, Buse J B, Taylor K. et al . Exenatide once weekly versus twice daily for the treatment of type 2 diabetes.  Lancet. 2008;  372 1240-1250
    Google Scholar
  • 7 Drucker D J, Nauck M A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.  Lancet. 2006;  368 1696-1705
    Google Scholar
  • 8 Gaede P, Vedel P, Larsen N. et al . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  N Engl J Med. 2003;  348 383-393
    Google Scholar
  • 9 Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.  Int J Clin Pract. 2006;  60 1654-1661
    Google Scholar
  • 10 Gerstein H C, Miller M E, Byington R P. et al . Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 2545-2559
    Google Scholar
  • 11 Holman R R, Paul S K, Bethel M A. et al . 10-year follow-up of intensive glucose control in type 2 diabetes.  N Engl J Med. 2008;  359 1577-1589
    Google Scholar
  • 12 Karasik A, Aschner P, Katzeff H. et al . Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes.  Curr Med Res Opin. 2008;  24 489-496
    Google Scholar
  • 13 Klonoff D C, Buse J B, Nielsen L L. et al . Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.  Curr Med Res Opin. 2008;  24 275-286
    Google Scholar
  • 14 Matthaei S, Bierwirth R, Fritsche A. et al . Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2.  Diabetologie. 2009;  4 1-33
    Google Scholar
  • 15 Mest H J. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.  Curr Opin Investig Drugs. 2006;  7 338-343
    Google Scholar
  • 16 Nathan D M, Buse J B, Davidson M B. et al . Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.   Diabetologia. 2006;  49 1711-1721
    Google Scholar
  • 17 Nathan D M, Buse J B, Davidson M B. et al . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.  Diabetes Care. 2008;  31 1-11
    Google Scholar
  • 18 Nauck M A, Heimesaat M M, Ørskov C. et al . Preserved incretin activity of glucagon-like peptide 1 [7 – 36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.  J Clin Invest. 1993;  91 301-307
    Google Scholar
  • 19 Nauck M A, Kleine N, Ørskov C. et al . Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7 – 36 amide) in type 2 (non-insulin-dependent) diabetic patients.  Diabetologia. 1993;  36 741-744
    Google Scholar
  • 20 Nauck M A, Meininger G, Sheng D. et al . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone.  Diabetes Obes Metab. 2007;  9 194-205
    Google Scholar
  • 21 Perry T, Holloway H W, Weerasuriya A. et al . Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.  Exp Neurol. 2007;  203 293-301
    Google Scholar
  • 22 Schwarz P E, Muylle F, Valensi P. et al . The European perspective of diabetes prevention.  Horm Metab Res. 2008;  40 511-514
    Google Scholar
  • 23 Sokos G G, Nikolaidis L A, Mankad S. et al . Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.  J Card Fail. 2006;  12 694-699
    Google Scholar
  • 24 Williams-Herman D, Round E, Swern A S. et al . Safety and tolerability of sitagliptin in patients with type 2 diabetes.  BMC Endocr Disord. 2008;  8 14
    Google Scholar
  • 25 Zinman B, Hoogwerf B J, Duran Garcia S. et al . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes.  Ann Intern Med. 2007;  146 477-485
    Google Scholar

Prof. Dr. med. Baptist Gallwitz

Medizinische Klinik IV, UKT

Otfried-Müller-Str. 10

72076 Tübingen

Phone: 07071/298-2093

Fax: 0707/29-5004

Email: baptist.gallwitz@med.uni-tuebigen.de

      >